Send to

Choose Destination
Ann Hepatol. 2017 Nov;16(Suppl. 1: s3-105.):s58-s67. doi: 10.5604/01.3001.0010.5498.

Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and therapeutic advances.

Author information

Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico.


Nonalcoholic liver disease (NAFLD) is a major emerging health burden that is a common cause of illness and death worldwide. NAFLD can progress into nonalcoholic steatohepatitis (NASH) which is a severe form of liver disease characterized by inflammation and fibrosis. Further progression leads to cirrhosis, which predisposes patients to hepatocellular carcinoma or liver failure. The mechanism of the progression from simple steatosis to NASH is unclear. However, there are theories and hypothesis which support the link between disruption of the bile acids homeostasis and the progression of this disorder. Previous studies have been demonstrated that alterations to these pathways can lead to dysregulation of energy balance and increased liver inflammation and fibrosis. In this review, we summarized the current knowledge of the interaction between BA and the process related to the development of NAFLD, besides, the potential targets for novel therapies.


Bile acids. NAFLD. Metabolism. Metabolic syndrome.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for IndexCopernicus
Loading ...
Support Center